Scarica l'app Stockscreener
14.72
3.16%
-0.48
Dopo l'orario di chiusura:
14.43
-0.29
-1.97%
Precedente Chiudi:
$15.20
Aprire:
$15.1
Volume 24 ore:
206.78K
Relative Volume:
1.23
Capitalizzazione di mercato:
$997.54M
Reddito:
$-9,000
Utile/perdita netta:
$-68.03M
Rapporto P/E:
-14.02
EPS:
-1.05
Flusso di cassa netto:
$-44.76M
1 W Prestazione:
+7.21%
1M Prestazione:
+9.12%
6M Prestazione:
-5.22%
1 anno Prestazione:
-20.13%
Intervallo 1D:
$14.60
$15.64
Intervallo di 1 settimana:
$13.17
$15.64
Portata 52W:
$12.56
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Nome
Pulse Biosciences Inc
Settore
Industria
Telefono
510-906-4600
Indirizzo
3957 POINT EDEN WAY, HAYWARD, CA
Confronta PLSE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
14.72 | 1.03B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
585.08 | 209.96B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.18 | 57.75B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.62 | 39.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
250.92 | 36.23B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
41.25 | 31.82B | 27.43B | 1.27B | 1.01B | 1.5829 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | Oppenheimer | Outperform |
| 2021-07-27 | Iniziato | Stephens | Overweight |
| 2021-03-11 | Iniziato | Maxim Group | Buy |
| 2021-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-12 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Pulse Biosciences Inc Borsa (PLSE) Ultime notizie
Will Pulse Biosciences Inc. (6L8) stock outperform value peersEarnings Overview Summary & Growth Focused Entry Reports - ulpravda.ru
Will Pulse Biosciences Inc. stock reach Wall Street targetsMarket Trend Review & Real-Time Volume Trigger Notifications - ulpravda.ru
Is MBX Biosciences Inc. stock positioned well for digital economyJuly 2025 Short Interest & Safe Entry Momentum Tips - ulpravda.ru
Why Pulse Biosciences Inc. stock remains resilient2025 Key Lessons & Daily Stock Momentum Reports - ulpravda.ru
Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsMarket Weekly Review & Safe Capital Allocation Plans - ulpravda.ru
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium - Bluefield Daily Telegraph
(PLSE) Volatility Zones as Tactical Triggers - Stock Traders Daily
What analysts say about Pulse Biosciences Inc 6L8 stockEarnings Growth Projections & Test Our Stock Screener — Free Forever - earlytimes.in
Chipmakers Recap: How Pulse Biosciences Inc 6L8 stock responds to bond market - moha.gov.vn
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
Total debt per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Positron (OTCMKTS:POSC) vs. Pulse Biosciences (NASDAQ:PLSE) Critical Comparison - Defense World
What drives Pulse Biosciences Inc 6L8 stock priceHigh Dividend Yield Stocks & High Profit Market Growth - earlytimes.in
MSN Money - MSN
Understanding the Setup: (PLSE) and Scalable Risk - Stock Traders Daily
Pulse Biosciences (PLSE): Valuation Check After FDA IDE Approval for nPulse Cardiac Ablation Trial - Sahm
Pulse Biosciences Updates Investors on Product Advancements - MSN
Pulse Biosciences, Inc (PLSE) Investor Outlook: Exploring A 44.74% Potential Upside - DirectorsTalk Interviews
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial - Sahm
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans - Sahm
Can Pulse Biosciences Inc. stock beat market expectations this quarterEarnings Recap Report & Growth Focused Stock Reports - Улправда
Forecast Cut: Will Pulse Biosciences Inc. stock outperform tech sector in 2025July 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
What technical signals suggest for Pulse Biosciences Inc. stockSell Signal & AI Driven Price Forecasts - Улправда
How buybacks impact Pulse Biosciences Inc. stock valueEarnings Growth Summary & Long-Term Capital Growth Strategies - Улправда
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Market Pulse: How Aura Biosciences Inc. stock performs in high volatility marketsWall Street Watch & Long-Term Safe Investment Ideas - Улправда
Aug Fed Impact: Can Pulse Biosciences Inc. (6L8) stock deliver double digit returnsQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - Улправда
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial - sharewise.com
How Pulse Biosciences Inc. stock responds to policy changesMarket Risk Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Can Pulse Biosciences Inc. stock resist market sell offs2025 Support & Resistance & Community Verified Trade Signals - DonanımHaber
FDA approves Pulse Biosciences’ atrial fibrillation trial By Investing.com - Investing.com Australia
How Pulse Biosciences Inc. stock benefits from tech adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - DonanımHaber
Short Covering: Can Pulse Biosciences Inc. stock beat market expectations this quarter2025 Top Decliners & Long-Term Growth Plans - Улправда
Pulse Biosciences wins FDA approval to begin PFA catheter study - MedTech Dive
Pulse Biosciences gains FDA IDE for NANOPULSE-AF trial - TipRanks
Pulse Biosciences IDE Approval for Atrial Fibrillation Study - TradingView — Track All Markets
[8-K] PULSE BIOSCIENCES, INC. Reports Material Event | PLSE SEC FilingForm 8-K - Stock Titan
Pulse Biosciences Receives FDA Approval to Launch Cardiac Catheter Ablation Study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation - Investing News Network
FDA approves Pulse Biosciences’ atrial fibrillation trial - Investing.com
Pulse Biosciences announces FDA IDE approval to initiate its nPulse cardiac catheter ablation system study - marketscreener.com
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study - TradingView — Track All Markets
Will Pulse Biosciences Inc. stock outperform tech sector in 2025Market Performance Recap & Scalable Portfolio Growth Ideas - Улправда
Pulse Biosciences Earnings Notes - Trefis
How (PLSE) Movements Inform Risk Allocation Models - Stock Traders Daily
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5%Here's What Happened - MarketBeat
Net current asset value per share of Pulse Biosciences, Inc. – MUN:6L8 - TradingView — Track All Markets
Pulse Biosciences drops 38% after InvestingPro’s "Overvalued" warning By Investing.com - Investing.com Australia
Pulse Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Pulse Biosciences Inc Azioni (PLSE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.26%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):